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Preface
The Nordic Council is an intergovernmental collaborative body for the five
countries, Denmark, Finland, Iceland, Norway and Sweden. One of the
committees, the Nordic Senior Executive Committee for Occupational Environ-
mental Matters, initiated a project in order to produce criteria documents to be
used by the regulatory authorities in the Nordic countries as a scientific basis for
the setting of national occupational exposure limits.
The management of the project is given to an expert group. At present the
Nordic Expert Group consists of the following members:
Gunnar Johanson (chairman) National Institute for Working Life, Sweden
Vidir Kristjansson Administration of Occupational Safety and Health,
Iceland
Kai Savolainen Finnish Institute of Occupational Health, Finland
Vidar Skaug National Institute of Occupational Health, Norway
For each document an author is appointed by the Expert Group and the national
member acts as a referent. The author searches for literature in different data bases
such as Toxline, Medline and Nioshtic. Information from other sources such as
WHO, NIOSH and the Dutch Expert Committee on Occupational Standards is
also used as are handbooks such as Patty's Industrial Hygiene and Toxicology.
Evaluation is made of all relevant scientific original literature found. In
exceptional cases information from documents difficult to access is used.
The present document is such an exceptional case. Very few peer-reviewed
reports on the toxicology of triglycidyl isocyanurate were found. The Nordic
Expert Group therefore decided to admit the inclusion of non peer-reviewed
reports on four conditions. Thus, to be included each report must be (1) judged to
be reliable and (2) relevant and important for the main conclusions. In addition,
(3) the report must have been cited and, thus, critically reviewed by at least one
other distinguished international or national body. Finally, (4) the nature of the
report should be clearly indicated in the text.
The document aims at establishing dose-response/dose-effect relationships and
defining a critical effect based only on the scientific literature. The task is not to
give a proposal for a numerical occupational exposure limit value.
The evaluation of the literature and the drafting of this document on triglycidyl
isocyanurate was made by M Ph Birgitta Lindell, and Dr Johan Montelius at the
National Institute for Working Life, Sweden. The draft document was discussed
within the Expert Group and the final version was accepted by the Nordic Expert
Group November 20, 2001, as its document.
Editorial work was performed by the Group's Scientific Secretary, Jill Järnberg,
and technical editing by Karin Sundström, both at the National Institute for
Working Life in Sweden.
We acknowledge the Nordic Council for its financial support of this project.
Jill Järnberg Gunnar Johanson
Scientific Secretary Chairman
Abbreviations
ANOVA analysis of variance
CICAD Concise International Chemical Assessment Document
CHO Chinese hamster ovary
CHL Chinese hamster lung
FEV1 forced expiratory volume in 1 second
GLP good laboratory practise
HSE Health and Safety Executive
LD50 lethal dose for 50% of the exposed animals at single administration
NICNAS the National Industrial Chemicals Notification and Assessment
Scheme
NOAEL no observed adverse effect level
TGIC triglycidyl isocyanurate
UK United Kingdom
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11. Introduction
Triglycidyl isocyanurate (TGIC) is an epoxy compound often used as a hardener.
The main use of TGIC is in the manufacture of polyester powder coatings (paints)
for metal finishing. Powder coatings usually contain between 4 and 10% TGIC.
TGIC has been used in weather-resistant powder coatings in Europe since the
1970s. Powder coated objects include garden steel furniture, car parts, metal
fencing, window and door frames but also electrical equipment, refrigerators,
washing machines and ovens. TGIC may also be used in inks in the printed circuit
board industry. The two-part inks contain approximately 60% TGIC in the
hardener component. Furthermore, TGIC has been used as an anti-tumour agent in
clinical trials, but owing to its severe local toxicity the use of TGIC was not
pursued (15, 20, 29, 33).
Normally, only studies published in peer-reviewed international scientific
journals are cited in criteria documents produced by the Nordic Expert Group.
However, in the case of TGIC very few peer-reviewed studies were found.
Therefore, non peer-reviewed studies have been referred to in this document on
condition that they have been cited in a review prepared by an international or
national body and are important for the conclusions. It is also indicated if the
original report has not been retrieved.
2. Substance identification (15, 16, 29)
IUPAC name 1,3,5-tris (oxiranylmethyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-
trione
Common name: triglycidyl isocyanurate
CAS number: 2451-62-9, 59653-73-5 (α-TGIC), 59653-74-6 (ß-TGIC)
Synonyms: TGIC; 1,3,5-triglycidyl isocyanurate;
1,3,5-triglycidyl-s-triazinetrione;
1,3,5-tris(2,3-epoxypropyl)-s-triazine-2,4,6(1H,3H,5H)-
trione; tris(2,3-epoxypropyl)isocyanurate
Trade names: TEPIC, Araldite PT 810, TK 10622
Molecular formula: C12H15N3O6
Molecular weight: 297.3 g/mol
Structural formula:
N N
N OO
O
O
O
O
2TGIC is manufactured and supplied as technical grade under the trade names
TEPIC and Araldite PT 810 (also known as TK 10622) (20, 29). There are two
stereoisomeric forms, α-TGIC and ß-TGIC, which differ in the orientation of the
glycidyl groups. Technical grade TGIC contains 90% α-and 10% ß-isomer (16).
3. Physical and chemical properties
α-TGIC ß-TGIC TEPIC Araldite PT 810
Purity (%) ≈90 >97
Melting point (°C) 105 156 90-125 95
Vapour pressure (kPa) 7.2·10-9 (20°C)
Flash point (°C) >170
Autoignition temp. (°C) >200
Density (g/cm3)a 1.420 1.460
Solubility in water (g/l) 10 (20°C) 0.53 (20°C) 9 (25°C) 8.7 (25°C)
Partition coefficient
(log Ko/w)
-0.8
a Temperature not given
References for data are 6, 15, 29
TGIC is a solid, which may occur as a white opaque powder or granules or as
clear crystals (16). It is an epoxy compound, where three glycidyl groups are
coupled to a triazine ring (33). TGIC has a low vapour pressure and no discernible
odour at room temperature (16, 20). It is soluble or slightly soluble (25°C) in
epichlorohydrin (<22%), methanol (7.3%), toluene (3%), and isopropanol (1%)
(20).
Dust explosions may occur if TGIC in powder or granular form is mixed with
air. The substance may polymerise after heating to more than 120°C for more than
12 hours, or under the influence of catalysts (20). In its molten state, TGIC reacts
easily with various functional groups in the presence of catalysts or promoters
(29). Molten TGIC reacts rapidly with primary and secondary amines, carboxylic
acids and anhydrides, thiols, phenols and alcohols (20). Combustion products
include oxides of nitrogen, carbon monoxide, carbon dioxide, ethene oxide, and
acrolein (5, 20).
4. Occurrence, production and use
TGIC does not occur naturally. It is produced industrially by reacting cyanuric
acid with excess epichlorohydrin. The worldwide production of TGIC is
approximately 7000-8000 tonnes per year (16, 20, 29). The two main technical
grades of TGIC used in the manufacture of powder coatings worldwide are
3Araldite PT 810 manufactured by Ciba-Geigy and TEPIC manufactured by Nissan
Chemical Industries (29).
TGIC is used mainly as a hardener in the thermosetting one-component
polyester powder coatings (33). In the manufacture of powder coatings, TGIC
granules are mixed with resin, pigments (if pigmented powder coatings), fillers
and additives. The mixture is heated until melting occurs and the melt is mixed to
ensure homogeneity. It is then extruded into a thin sheet, which cools and
solidifies. The solid material is chipped, milled, sieved and packed as a fine
powder (29). TGIC is partially cross-linked to the polyester resin. The powder
coatings usually contain 4-10% TGIC and are sprayed onto metal objects by an
electrostatic process. The coated metal objects are then placed in an oven. At a
temperature of about 200°C the resin melts, flows, and chemically cross-links to
form a paint film (20, 29). The TGIC in powder coatings after application to metal
particles is fully cross-linked and is bound in a solid matrix. The coatings are
durable and resist ultraviolet damage and are therefore typically used in out-door
applications (16, 20).
In addition, TGIC is used in electrical insulation materials, resin-moulding
systems, laminated sheetings, silk-screen printing coatings, tools, inks, adhesives,
lining materials, and stabilisers for plastics (33). Solder ”mask” inks used in the
printed circuit board industry are two-part inks containing approximately 60%
TGIC in a powdered form in the hardener component (16, 20). The inks are
applied by curtain coating, electrostatic spraying, or by screen-printing. The
coated circuit board is finally passed through an oven at 150°C to complete the
curing (20).
In Sweden, TGIC is imported as technical grade TGIC or as an ingredient of
products. 15 products containing TGIC were imported to Sweden in 1999
(including technical grades of TGIC) and the total amount of TGIC imported was
76-91 tonnes. About 31 tonnes was used in the manufacturing of 4 products
containing TGIC. Technical grade TGIC was not manufactured in the country.
Technical grade TGIC was used as raw material in the paint industry, whereas
imported or manufactured products containing TGIC were used in industry for
fabricated metal products/industry for the treatment and coating of metals and in
the construction industry. Minor uses for products containing TGIC were as solder
”mask” inks or as photoresists (Product Register at the Swedish National
Chemical Inspectorate, personal communication). In Norway in the year 2000,
TGIC was an ingredient of a few paints used for production of metal products.
However, the total amount of TGIC could not be given (Norwegian Product
Register, personal communication). In Finland, 9 products containing 1-45%
TGIC were used in 2000. Two of these products were used in the manufacturing
of electronical components, whereas 7 products were used in painting. The total
amount of TGIC could not be given (Finnish Product Register, personal
communication). In Denmark, TGIC is imported as technical grade TGIC or as an
ingredient of products. In the year 2000, 9 products were reported to contain
TGIC and the total amount of TGIC approached 10 tonnes. Technical grade TGIC
was used in the manufacturing of painting products. The products containing
4TGIC were mainly paints and lacquers used in the iron- and metal industry or in
the manufacturing of means of transport (Danish Product Register, personal
communication).
The anti-tumour properties of α- and ß-TGIC have been investigated in various
transplantable mouse tumour systems. Both stereoisomers displayed a high
therapeutic activity, but α-TGIC was superior to the ß-isomer in prolonging the
lifespan of treated animals and in inducing long-term survival, probably due to a
higher water solubility (3, 4, 11, 14, 36, 39). In vitro studies measuring cells killed
by the drug indicated that neoplastic cells were more susceptible to α-TGIC than
non-neoplastic cells (39). α-TGIC has also been available as an experimental
anti-neoplastic agent and was used in human clinical trials in the early 1980s (29).
However, it has been suspected that some of the clinical trials were conducted
with TGIC mixtures, rather than pure α-TGIC as reported (14).
5. Occupational exposure data
Occupational exposure to TGIC may occur during the manufacture of TGIC and
the manufacture and use of products containing TGIC (20). The most likely routes
of occupational exposure are inhalational and dermal. A fraction of the inhaled
material will be swallowed, and there may also be some oral ingestion (19, 29).
Activities likely to cause high levels of exposure during the manufacture of TGIC
powder coatings are weighing out of TGIC, filling hoppers, mixing, transfer of
powder mixes in open vessels, extrusion, milling, bagging, cleaning-up spills and
cleaning equipment. The highest level of exposure to TGIC will occur when
handling technical grade TGIC (29). However, particle size data on technical
grade TGIC as granules indicate that only very small fractions are respirable. Of
TEPIC particles, 99.6% are >400 µm and only 0.003% are <10 µm (29).
Exposure to TGIC during the use of products containing TGIC may occur in
factories and paint shops, where TGIC powder coatings are sprayed onto metal
objects prior to curing in ovens. There is a considerable potential for airborne dust
generation during decanting of the powder in preparation for spraying (filling
hoppers). The method of application (spraying) also provides considerable
potential for exposure to powder coatings, especially if the area is not fully
enclosed and the objects are manually sprayed (29). Furthermore, certain cleaning
operations (cleaning-up spills, cleaning equipment, cleaning spray booths) may
lead to exposure to large amounts of TGIC (29, 37). Nevertheless, some data
indicate that TGIC powder coatings have a low fraction of particles in the
respirable range (29). Generally, the particle size of 90-95% of the powder coating
is >10 µm (20).
Data describing actual exposure levels at workplaces are limited. No monitoring
data are available for the manufacture of TGIC and data for the manufacture and
use of TGIC containing products are restricted to powder coatings. These data
have shown marked differences in the air levels of TGIC between and within
workplaces (Table 1). In an Australian powder coating manufacturing plant the
5levels of atmospheric TGIC in July/August 1991 varied between 0.023 and
1.34 mg/m3 (time-weighted average, TWA). Levels of total dust were up to
24.9 mg/m3. The data showed that dust levels for different operators performing
the same job varied considerably. Later work practices were improved and dust
levels were considerable lowered. In October 1991, the levels of TGIC (TWA)
were between 0.00001 and 0.03 mg/m3 (20, 29). In a Japanese powder coating
manufacturing plant TGIC levels up to 0.035 mg/m3 (TWA) and dust levels up to
1.12 mg/m3 were measured in 1991 (20, 29). In 5 plants manufacturing TGIC-
containing powder coatings in the United Kingdom (UK) in 1994, TGIC levels
Table 1. Workplace concentrations of TGIC in various types of industries
Industry Process/work operation Exposure level (TWA)
(mg/m3)
Ref
manufacture of make up 0.032-0.19 (20, 29)
powder coatings extruder
mill
laboratory
0.023-0.27
0.085-1.34
0.047
(20, 29)
(20, 29)
(20, 29)
manufacture of
powder coatings
warehouse
mixing
extruder
mill
bulk
laboratory
0.002-0.007
0.00001
0.003-0.013
0.006
0.004
0.004-0.030
(20, 29)
(20, 29)
(20, 29)
(20, 29)
(20, 29)
(20, 29)
manufacture of
powder coatings
weighing raw materials
filling raw materials
mixing
pulverisation
packing
cleaning work: mixer
cleaning work: pulveriser
cleaning work: cyclone
cleaning work: sieve
cleaning work: packing hopper
0.005*
0.004*
trace*
0.002*
0.009*
0.006*
trace*
0.009*
0.035*
0.005*
(20, 29)
(20, 29)
(20, 29)
(20, 29)
(20, 29)
(20, 29)
(20, 29)
(20, 29)
(20, 29)
(20, 29)
manufacture of
powder coatings
weighing
milling
0.01-0.44
mean: 0.1
mean: 0.27
mean: 0.08
(16, 20, 37)
(16, 20, 37)
(16, 37)
(16, 37)
use of powder coatings spray painting <0.001-6.5 (20, 29)
use of powder coatings e.g. spraying
cleaning, colour changes
0.001-1.5
mean: 0.24
mean**: 0.95
(16, 20, 37)
(16, 20, 37)
(16, 37)
*determination of TEPIC
**short-term exposure
6ranged from 0.01 to 0.44 mg/m3 with a mean of 0.1 mg/m3 (8-hour TWAs).
Corresponding total inhalable particulate levels were 1.1-64 mg/m3 (8-hour
TWAs). The highest exposures were found during weighing (TGIC mean:
0.27 mg/m3) and milling (TGIC mean: 0.08 mg/m3). High exposures were,
however, found for all the tasks monitored (weighing, mixing, extrusion, milling,
packing, cleaning). The high exposures were generally due to poor working
practices (16, 20, 37).
In a survey of 8 spray painting workplaces in Australia in 1991 the TGIC
content in dust from 7 workplaces was up to 6.5 mg/m3 (TWA; personal air
monitoring). Total dust levels were up to 132 mg/m3 (20, 29). The results of a
survey of 16 similar workplaces in the UK in 1994 showed TGIC levels between
0.001 and 1.5 mg/m3 (8-hour TWAs; mean: 0.24 mg/m3). Corresponding total
inhalable particulate levels were 0.2-131 mg/m3 (8-hour TWAs). Exposures were
high during all the tasks measured (spraying, loading, cleaning). Furthermore,
high full-shift exposures to TGIC were measured for both manual spray operators
and sprayers at automated booths. High short-term exposures were measured
during cleaning and colour changes. The high exposure levels of TGIC in the
investigated workplaces in the UK were generally attributed to poor working
practices (16, 20, 37).
 6. Measurement and analysis of workplace exposure
A rough estimate of exposure to free TGIC in coating powders can be made by
measuring exposure to total inhalable particulate. After collection on filters and
gravimetric analysis, the exposure to free TGIC can be calculated from the com-
position of the coating powder (17, 18).
A more accurate method for the analysis of TWA concentrations of TGIC, and
premix and coating powders containing TGIC in air has been described by the UK
Health and Safety Executive (HSE) (18). Premix is defined as formulated and
mixed coating powder prior to extrusion in manufacture, and coating powder as
the extruded and milled powder supplied by manufacturing companies to users.
The method described is suitable for personal sampling in the breathing zone but
can also be used for background or fixed location monitoring. Only monomeric
TGIC will be measured. Sampling is carried out according to a general method for
sampling of total inhalable dust (17), i.e. a measured volume of air (a suitable
sample volume is 200 l) is drawn through a silanised glass fibre filter mounted in
a sampler for inhalable dust. A gravimetric screening method can be used as a
preliminary screening method for TGIC (18). For a more specific analysis high
performance liquid chromatography is used. It is important to analyse the samples
promptly, as decomposition of TGIC is rapid. For sample volumes of 200 l, the
method is validated between 0.01 and 0.2 mg/m3 pure TGIC and the detection
limit is approximately 0.18 µg TGIC per sample corresponding to 0.9 µg/m3.
77. Toxicokinetics
7.1. Uptake
No data have been found in the peer-reviewed literature.
7.2. Distribution
No data have been found in the peer-reviewed literature.
7.3. Biotransformation and excretion
α-TGIC is rapidly metabolised by rat liver. When α-TGIC was incubated (1 mM)
with hepatic microsomes, rapid disappearance of the parent drug was observed in
the presence or absence of NADP+. When inactivated microsomes were used in
the incubation mixture, no loss of α-TGIC occurred. These results suggest that
α-TGIC is metabolised by microsomal enzymes other than monooxygenases.
Epoxide hydrolysis products were detected in hepatic microsomal incubation
mixtures and cyclohexene oxide inhibited α-TGIC metabolism, suggesting that
epoxide hydrolase is responsible for the biotransformation. Rat lung preparations
did not significantly metabolise α-TGIC (2).
It has been shown that there is considerable variation in epoxide hydrolase
activity between individuals in humans (25).
The disposition of α-TGIC following intravenous administration of 3 and
10 mg/kg body weight to rabbits has been studied. At these doses plasma
elimination of parent drug was very rapid with a half-time of <5 minutes. When
14C-labeled α-TGIC (10 mg/kg body weight) was intravenously administered to
rabbits plasma elimination of radioactivity was much slower than that of parent
drug. The radioactivity was equally distributed between plasma and red blood
cells. The 24-hour urinary recoveries of parent drug and total radioactivity were
<1% and about 65%, respectively. When 14C-labeled α-TGIC (10 mg/kg body
weight) was administered to rabbits by stomach tube parent drug was not detected
in plasma and plasma concentrations of total radioactivity were lower compared to
those observed following intravenous administration. The 24-hour urinary re-
coveries of radioactivity were about 30%. These data suggest extensive meta-
bolism of TGIC (2).
Disposition of α-TGIC has also been studied in patients. When patients received
α-TGIC as intravenous infusions at constant rates (12.5-50 mg/min) plasma
concentrations rapidly reached plateau values and remained constant during the
infusion. Plasma steady-state concentrations increased and total-body clearance
values decreased as the rate of infusion increased. The 24-hour urine recovery of
the parent drug was less than 1% for all patients. The mean plasma elimination
half-time was 1.4 minutes for 9 patients given 140-500 mg/m2 body surface for 3-
10 minutes (2, 34). In another study a mean half-time of 0.9 minutes was reported
following short intravenous infusion of α-TGIC to 5 patients (28).
88. Biological monitoring
No data have been found.
9. Mechanism of toxicity
No information is available concerning the mechanism of toxicity of TGIC.
Considering that TGIC contains three reactive epoxide groups it is plausible
that it reacts with macromolecules causing different adverse effects, e.g. inducing
mutations by binding to DNA and sensitisation by binding to proteins. Dose-
dependent increases in TGIC-DNA adduct formation were reported in a non peer-
reviewed studya (cited in 15, 20 and 29).
10. Effects in animals and in vitro studies
10.1 Irritation and sensitisation
No peer-reviewed studies concerning eye or skin irritation have been found.
However, there are three non peer-reviewed eye irritation studies from
manufacturers. In these studies 0.1 g of TGIC was inserted into the conjunctival
sac of rabbits followed by a 7-day observation period. In one of the studiesb (cited
in 29) TGIC was not an eye irritant, but in the other two studies c d (both cited in
15, 20 and 29), conducted according to Environmental Protection Agency (1978)
guidelines, severe eye reactions were noted (corneal opacity, redness, chemosis,
discharge).
No peer-reviewed studies on the potential of TGIC to induce contact allergy in
animals have been found.
10.2. Effects of single exposure
The dose that is lethal for 50% of the animals at single administration (LD50) of
α-TGIC, evaluated over a 14 days observation period, was 105 mg/kg body
weight at intraperitoneal administration in mice. Because of the poor solubility of
ß-TGIC, the acute LD50 of this isomer could not be determined. All mice survived
a single intraperitoneal dose of 650 mg/kg body weight (3).
                                                                  
aCiba-Geigy, 1990. Potential for DNA binding of Araldite PT 810 (No PS32-01903). Basel, Ciba-
Geigy Ltd.
bCiba-Geigy, 1979. Eye irritation in the rabbit after single application of TK 10622 (No.790338).
Basel, Ciba-Geigy Ltd. Report not retrieved.
cCiba-Geigy, 1979. Eye irritation in the rabbit after single application of TK10622/3 (No.790341).
Basel, Ciba-Geigy Ltd. Report not retrieved.
dCiba-Geigy 1982. Acute eye irritation study in the rabbit with TK10622 (No.820696). Basel,
Ciba-Geigy Ltd. Report not retrieved.
910.3. Effects of short-term exposure
The daily dose of α-TGIC causing 50% mortality at intraperitoneal administra-
tion, evaluated over a 14 days observation period, was found to be approximately
58 mg/kg body weight when a 9 consecutive days treatment was used in mice. A
50% mortality was obtained with 5 intraperitoneal doses of 350 mg/kg body
weight, when the ß-isomer was used (3).
In a non peer-reviewed 13-week toxicity/fertility studya (cited in 20 and 30),
conducted in compliance with Good Laboratory Practice (GLP) regulations,
groups of 10 male rats were given diets containing 0, 10, 30 or 100 ppm TGIC.
The dose levels corresponded on average to 0, 0.7, 2.1 or 7.3 mg/kg body
weight/day. No exposure-related clinical effects or deaths were observed.
However, slightly lower body weight gain was seen at 100 ppm and in 4 animals
from this group haemosiderosis and/or congestion in the mesenteric lymph nodes
was noted.
10.4. Mutagenicity and genotoxicity
A few peer-reviewed published studies on the in vitro mutagenic/genotoxic effects
have been found and are described below.
TGIC has been shown to be mutagenic in two strains of Salmonella typhi-
murium (TA98 and TA100) in the Ames test (40) both in the presence and
absence of a metabolic activation system (S9). A slight decrease in mutagenic
activity was seen in the presence of S9-fractions in both Salmonella strains. The
purity of the TGIC tested was >79%.
TGIC (purity >79%) was tested for its ability to induce sister chromatid
exchanges and chromosomal aberrations in cultured Chinese hamster ovary
(CHO) cells using a standard protocol, as part of a National Toxicology Program
project to evaluate the relationship between genotoxicity and carcinogenicity (22).
TGIC was clearly positive in both test systems. The lowest concentration of TGIC
that induced a significant frequency of sister chromatid exchange was 0.066 µg/ml
(concentration range tested: 0.066-0.66 µg/ml) in the absence of S9-mix and
1.98 µg/ml (concentration range tested: 1.98-19.8 µg/ml) in the presence of S9-
mix. Details of the chromosomal aberration test are described below (35).
TGIC was tested for the induction of chromosomal aberrations in two cultured
mammalian cell systems, Chinese hamster lung (CHL) cells and CHO cells, in a
study conducted to compare the two test systems (35). TGIC was clearly positive
in both cell systems without metabolic activation. In CHL cells, TGIC was tested
at 1.2, 2.5 and 5.0 µg/ml for 24 and 48 hours. Chromosomal aberrations (mainly
chromatid gaps, chromatid breaks, and chromatid exchanges) were seen at all dose
levels except at the two highest doses at 48 hours which were toxic to the cells. In
aCIT, 1995. 13-week toxicity study and fertility study by oral route (dietary admixture) in male rats
with PT 810 (TGIC) Miserey, Centre Internationale de Toxicologie.
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CHO cells chromosomal aberrations (simple and complex aberrations) were seen
when the cells were treated with 3.0, 10.0 and 30.0 µg/ml of TGIC for 8 hours.
The highest dose tested, 50.0 µg/ml, was toxic to the cells. However, the presence
of S9 gave negative results in the CHL cell system when TGIC was tested at the
same concentrations as used in the absence of S9 but with a slightly different time
schedule. A positive result was obtained in the CHO cell system in the presence of
S9 although the effect was slightly reduced at the doses tested (10.0, 30.0 and
100.0 µg/ml). These inconsistent results in the presence of an added metabolic
activation system may, according to the authors, be due to the fact that higher
doses of TGIC were used in CHO cells than in CHL cells. It could also be the
result of differences in treatment protocols (35).
The study of Sofuni et al. (35) has later been repeated in a multilaboratory
comparison study where in vitro tests for chromosomal aberrations in CHO and
CHL cells were tested with the same protocol (13). TGIC gave strong positive
results in both cell types with and without metabolic activation in all participating
laboratories. The dose levels that gave positive results were higher with S9 than
without, suggesting that S9 interferes with the activity of TGIC. The earlier
reported negative results in CHL cells in the presence of S9 reported by Sofuni et
al. (35) were concluded by the authors to be due to testing with too low concentra-
tions of TGIC (13).
Several non peer-reviewed studies on the in vivo mutagenic/genotoxic effects of
TGIC (cited in 15, 20, 29) are summarised in Table 2.
10.5. Effects of long-term exposure and carcinogenicity
No peer-reviewed studies were found concerning the carcinogenicity of TGIC.
However, the carcinogenic potential of TGIC was examined in a non peer-
reviewed studya (cited in 30) performed in compliance with GLP. In this study
TGIC was administered by dietary admixture to groups of 50 male rats at
concentrations of approximately 0, 10, 30 and 100 ppm (corresponding to 0, 0.4,
1.3 and 4.4 mg/kg body weight/day) for up to 99 weeks or 300 ppm (13.6 mg/kg
body weight/day) for 63 weeks. The animals in the 300 ppm group were killed at
week 63 due to the high level of mortality (the cause of death was possibly a
histamine-related hypotension). TGIC did not show a carcinogenic potential at
any dose level. At 300 ppm lower food consumption and a marked decrease in
body weight gain was recorded as well as poor clinical condition.
Histopathological investigations (300 ppm) revealed a significantly higher
incidence of mastocytosis, haemosiderosis and sinusal haemorrhage in the
mesenteric lymph nodes and lymphoid depletion in the spleen and a high
incidence of dilatation of some intestinal segments. In addition, a higher incidence
of hyposecretion and small tubulo-alveolar units in the prostate was found.
aCIT, 1999. Carcinogenicity study in male rats with TGIC (1,3,5-triglycidyl isocyanurate).
Miserey, Centre Internationale de Toxicologie.
11
Hematological changes (week 52: a higher neutrophil count and monocyte count,
lower lymphocyte count; week 63: lower total leukocyte count) were also noted.
These findings were attributed to treatment. No indication of treatment-related
non-neoplastic changes was seen in the 10, 30 and 100 ppm groups and the no
observed adverse effect level (NOAEL) in the study was considered to be
100 ppm.
In a satellite studya (cited in 30) the subchronic toxicity of TGIC was evaluated
over a 26-week treatment period. Groups of 10 male rats were given 0, 100 or
300 ppm (0, 5.8 or 16.7 mg/kg body weight/day) TGIC in the diet. No mortality or
clinical signs considered as substance-related occurred during the treatment
period, and no adverse effects were observed at 100 ppm. At 300 ppm, the
principal signs of toxicity were markedly lower body weight gain and food
consumption. Other effects reported at this dose level were lymphoid depletion of
spleen and thymus and hyposecretion of prostate and seminal vesicles, all
correlating with lower organ weights (p>0.05). Furthermore, a higher weight of
the mesenteric lymph nodes, associated with haemosiderosis, plasmocytosis,
mastocytosis and sinusal haemorrhages, was seen. A slightly lower mean total
leukocyte count was also found at 300 ppm.
10.6. Reproductive and developmental studies
No information concerning reproductive and developmental effects of TGIC was
found in the peer-reviewed literature.
A non peer-reviewed toxicity/fertility studyb (cited in 20 and 30) conducted in
compliance with GLP is available, but it should be noted that the highest concen-
tration used in this study was not the maximum tolerated dose. Groups of 10 male
rats were given diets containing 0, 10, 30 or 100 ppm TGIC, corresponding to 0,
0.7, 2.1 or 7.3 mg/kg body weight/day (mean) for 13 weeks. After 64 days of
treatment each male was placed with two untreated females for mating. Decreases
in the mean number of spermatozoa in treated groups (5%, 13% and 23% com-
pared to the control group) were reported, but without any statistical analysis.
According to the National Industrial Chemicals Notification and Assessment
Scheme (NICNAS) (30) the decreases were not significant when analysed by
analysis of variance (ANOVA), but no details on the statistical procedures were
given. Reanalysis of the raw data, performed by the Nordic Expert Group during
the elaboration of the present criteria document, confirmed that there was no
statistically significant difference between the dose groups (ANOVA, SPSS
software, v.10.0). However, the test for linear trend showed a significant
(p=0.015), dose-related decrease in sperm count. The mean spermatozoa viability
aCIT, 1999. Carcinogenicity study in male rats with TGIC (1,3,5-triglycidyl isocyanurate).
Miserey, Centre Internationale de Toxicologie.
bCIT, 1995. 13-week toxicity study and fertility study by oral route (dietary admixture) in male
rats with PT 810 (TGIC) Miserey, Centre Internationale de Toxicologie.
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in treated groups was similar to that in the control group and the decrease in the
number of spermatozoa did not impact fertility outcomes or embryonic and pup
development. No changes or effects were seen compared to controls in a number
of parameters studied (pre- and post-implantation losses, number of live foetuses,
foetal body weights, sex ratios, number of live born, viability 4 and 21 days post-
partum, pup weight day 1-21, external anomalies, malformations, physical and
reflex development of pups).
In a non peer-reviewed oral studya (cited in 20 and 29) chromosomal aberrations
and cytotoxicity have been reported in mouse spermatogonial cells at 115 mg
TGIC/kg body weight.
In a non peer-reviewed inhalation studyb (cited in 15, 20 and 29) effects on
mouse spermatogonial cells were measured by the induction of chromosomal
aberrations. Mice were exposed to 0, 2.5, 10 or 50 mg TGIC/m3 (purity not stated;
particle size range 2.5-3.5 µm) for 6 hours per day for 5 consecutive days. The
results of this study were inconclusive since the number of analysable spermato-
gonial metaphase cells in the two highest dose groups was too small. Furthermore,
the number of chromosomal aberrations in the control was unexpectedly high. The
study indicates that TGIC was cytotoxic to spermatogonial cells at the two highest
dose levels but the cytotoxic ratio was not calculated.
A reduction in male fertility, i.e. number of sperm-positive and pregnant
females, has been reported in a non peer-reviewed dominant lethal mutation studyc
(cited in 20 and 29). Male mice were exposed by inhalation to 0, 2.5, 10 or 50 mg
TGIC/m3 (purity not stated; particle size range 2.5-3.5 µm) for 6 hours per day for
5 consecutive days. General toxicity was observed at 50 mg/m3 and included
death (10%), reduction in body weight during exposures (persisting through the
2nd mating week), and persistent ocular discharge and swelling. After exposure
the male mice were bred to naive females. Females were replaced weekly for a
total of 8 weeks. A reduction in male fertility was observed in the highest dose
group for the first 3 mating weeks and for mating week 6. At 10 mg/m3 a
reduction in male fertility was observed for the 3rd mating week. The authors
conclude that effects observed during this period of the mating regime correspond
to effects on mature sperm, maturing spermatids and Type B spermatogonia. The
NOAEL for general toxicity was 10 mg/m3 and the NOAEL for effects on fertility
was 2.5 mg/m3. There were no observable dominant lethal effects following
exposure.
aSafepharm, 1992. TGIC technical and TGIC ten per cent powder: Chromosome analysis in mouse
spermatogonial cells, comparative inhalation study (No. 14/75) [draft]. Derby, Safepharm
Laboratories Ltd. Report partly retrieved.
bBushy Run, 1992. PL90-810: Chromosomal aberrations assay in mouse spermatogonial cells (No.
54-520). Export, PA, Bushy Run Research Center.
cBushy Run, 1992. Dominant lethal assay of inhaled PL 90-810 dust in CD-1 mice (No. 54-515).
Export, PA, Bushy Run Research Center.
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11. Observations in man
11.1. Irritation and sensitisation
11.1.1. Irritant and allergic (type IV allergy) contact dermatitis
No studies on the irritant effect of TGIC in humans have been found in the peer-
reviewed literature.
Seventeen cases of allergic contact dermatitis to TGIC, verified by patch
testing, have so far been described in the literature; 1 in the production of TGIC,
9 from the manufacturing of powder paints containing TGIC, 5 from the use of
TGIC-containing powder paints, and 2 from contact with TGIC containing
hardeners for epoxy acrylate ink. A weakness in these studies is that in most cases
the purity of TGIC used in patch testing is not stated. The studies are summarised
in Table 3.
11.1.2. Occupational asthma
A case of occupational asthma has been described by Piirilä et al. (33). The
patient was a healthy 36-year-old non-smoking man who had worked mainly as a
spray painter, using a polyester powder paint containing 4% TGIC as a hardener.
After 4 years of work with the powder paint an allergic contact dermatitis to TGIC
was diagnosed (see Table 3). A year later he had symptoms of dyspnoea,
especially during and after workdays and also suffered from wheezing dyspnoea
at night and during exercise. The symptoms were relieved during weekends.
Spirometry showed slight obstruction, the blood eosinophils and serum total IgE
levels were elevated, and a histamine challenge test showed slight bronchial
hyperreactivity. A skin-prick test to TGIC as well as a measurement of TGIC
specific IgE were negative. A challenge test with paint containing 4% TGIC
induced a late 23% fall and a test with 4% TGIC (stated to be “pure”) in lactose
induced a late 19% fall in forced expiratory volume in 1 second (FEV1). Both
immediate and late reactions were seen in peak expiratory flow. A lactose control
challenge test was negative. The patient’s respiratory disease was diagnosed as
occupational asthma caused by TGIC used as a hardener in the polyester powder
paint. No conclusion could be drawn about the underlying mechanism(s) for the
patient’s asthma.
An additional case of occupational asthma has been reported (26). The patient,
a 38-year-old man, first presented with an allergic contact dermatitis to TGIC (see
Table 3). For 3 years he had been working with polyester powder pigments.
Shortly after the cutaneous signs appeared he developed respiratory symptoms,
i.e. rhinitis, cough, dyspnoea, and wheezing. His symptoms decreased during
weekends and cleared completely on vacation. Histamine challenge tests showed
bronchial hyperreactivity and the total serum IgE level was elevated. The
occupational asthma was confirmed by bronchial provocation testing: two
challenges to an aerosol of lactose containing 0.05 and 0.1% TGIC (approximate
16
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purity 90%) led to a maximal decrease in FEV1 of 22 and 31% after 6 and 4
hours, respectively. A control test using an aerosol of lactose powder was
negative.
11.2. Effects of single and short-term exposure
α-TGIC was used in human clinical trials as an anti-tumour agent in the early
1980s (15, 20, 29). In these cases the drug was infused intravenously to cancer
patients and was administered with a variety of dosing schedules. Toxic signs
included myelosuppression (leukopenia, thrombocytopenia), nausea and
vomiting, but the main dose-limiting toxic effect was thrombophlebitis at the
injection site, sometimes associated with cutaneous flare reactions over the vein
(8, 28, 32, 34). However, these data were derived from patients that were
seriously ill and some of the systemic effects seen may have been the result of
previous chemotherapy treatment. Furthermore, the studies involved the rapid
intravenous infusion of α-TGIC. Thus, these studies are of limited relevance for
the occupational setting.
11.3. Effects of long-term exposure
No data have been found.
11.4. Genotoxic effects
No data have been found.
11.5. Carcinogenic effects
No data have been found.
11.6. Reproductive and developmental effects
No data have been found.
12. Dose-effect and dose-response relationships
12.1. Single/short-term exposures
Very few peer-reviewed data concerning effects of TGIC in animals after
single/short-term exposures have been found (Table 4). A non peer-reviewed
inhalation study reports reduced fertility in male mice at an exposure level of 10
and 50 mg/m3, 6 hours/day for 5 consecutive days. No effect on fertility was seen
at 2.5 mg/m3. Another non peer-reviewed study indicate a dose-related decrease in
the number of spermatozoa in rat at peroral administration of TGIC for 13 weeks,
in dose levels ≥ 0.7 mg/kg body weight/day. Lower dose levels were not tested
(Table 4).
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12.2. Long-term exposures
There are no long-term exposure data available for TGIC in the peer-reviewed
literature.
In a non peer-reviewed study a marked decrease in body weight gain and
remarkably high incidences of non-neoplastic histopathological changes were
recorded in male rats receiving doses of 300 ppm TGIC (approximately
13.6 mg/kg body weight/day) in the diet for 63 weeks. The principal findings
were increased mortality, mastocytosis in the lymph nodes and depletion of the
spleen lymphoid cells. Some hematological changes were also observed at this
dose level. No adverse effects were seen at lower dose levels, when TGIC was
given in the diet for up to 99 weeks. The NOAEL in the study was considered to
be 100 ppm (approximately 4.4 mg/kg body weight/day) (Table 4).
13. Previous evaluations by national and international bodies
The UK HSE published a toxicity review on TGIC in 1992 (15). Most of the
information was derived from non peer-reviewed studies. The major conclusions
were: A number of reports indicate that TGIC is capable of causing skin sensitisa-
tion in occupationally exposed workers. One study in guinea pigs indicates that
the compound has skin sensitisation potential. TGIC appears to be of moderate
acute toxicity to rats. Kidney damage has been found after repeated exposure.
TGIC has been shown to cause severe eye irritation in rabbits. It is mutagenic in
vitro and has shown genotoxic effects in rodents in vivo. Clastogenic effects in
bone-marrow cells and cytotoxicity and chromosomal aberrations in male germ
cells have been observed. A decrease in male fertility has been shown in one
study in mice. In a Summary Criteria for Occupational Exposure Limits (16)
based on the HSE review (15) the basis for setting a limit was stated: TGIC is a
direct-acting genotoxic substance capable of expressing this activity in vivo.
Given the chemically reactive nature of TGIC, there are concerns for mutagenic
effects at site of contact tissues. The same report suggests that the mutagenic
effects of TGIC are non-threshold phenomena, and consequently it is not possible
to set a health-based occupational exposure limit for such substances (16).
An assessment of TGIC made under the Australian NICNAS, mainly based on
non peer-reviewed studies, was published in 1994 (29). From the assessment of
the hazards of TGIC it was concluded that the chemical is a hazardous substance,
is toxic by oral and inhalational routes, a skin sensitiser, genotoxic and capable of
causing serious eye damage. From the assessment of the known hazards of TGIC,
overseas experience and air monitoring data, it was stated that TGIC is unlikely to
cause adverse human health effects if the appropriate control measures and
atmospheric monitoring strategy are implemented. However, the lack of chronic
data makes it difficult to predict the long-term health effects in workers exposed
to TGIC. As a result of new data becoming available, a second assessment of
20
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TGIC was published by NICNAS in 2001 (30). This assessment has evaluated
new animal studies including oral toxicity/fertility, carcinogenicity and contact
hypersensitivity studies, in addition to human case reports of respiratory sensitisa-
tion. It was stated that new human data confirmed that TGIC is a skin sensitiser
and also demonstrated that it is a respiratory sensitiser. Furthermore, it was
concluded that animal studies indicate that TGIC causes severe effects after
repeated exposure. The principal effects were lower body weight, mastocytosis in
lymph nodes and depletion of spleen lymphoid cells. TGIC was also regarded not
carcinogenic in male rats. Further, NICNAS stated that a recent fertility study in
rats provides some evidence that TGIC does not affect male fertility. However, it
was also stated that several data gaps remain.
A Concise International Chemical Assessment Document (CICAD) on health
effects of TGIC was published by the International Programme on Chemical
Safety, World Health Organization in 1998 (20). The most important conclusions
from the evaluation of health effects (mainly based on the NICNAS document
(29) and non peer-reviewed studies) were as follows: The only reported health
effects in humans are contact dermatitis and one case of respiratory sensitisation.
TGIC produces serious eye irritation and is a skin sensitiser in animals. Animal
studies have revealed renal, lung, gastric/duodenal and sperm cell damage. The
chemical has produced positive results in in vitro genotoxicity studies. Genotoxic
effects have also been observed in vivo in somatic cells and germ cells in the
testes. The demonstrated ability for TGIC to cause genetic damage raises concern
over potential carcinogenic and reproductive effects. Owing to its genotoxic and
sensitisation effects, workplace exposures should be maintained at the lowest
practicable level. According to the CICAD (20) TGIC is a direct-acting mutagen,
and it is not possible to identify a level of exposure below which there would be
no risk to human health.
The American Conference of Governmental Industrial Hygienists (ACGIH)
published a documentation of TGIC in 2001 (1). The major conclusions were:
Hematopoietic effects were observed in humans, mice and dogs as a result of
repeated intravenous infusions with α-TGIC. Dose levels below 2.3 mg/kg
body weight did not result in hematopoietic effects to human subjects. Repeated
inhalation exposures in mouse spermatogonial chromosome aberration studies
resulted in cytotoxicity to spermatogonial cells and increased incidence of chromo-
somal aberrations. Spermatogonial cell cytotoxicity was the most sensitive index of
toxicity with NOAELs of 7.8 mg/m3 (nose-only) and 2.5 mg/m3 (whole-body).
Fertility effects in mice were observed in an inhalation-exposure dominant lethal
assay; marginal effects were noted at 10 mg/m3  with a NOAEL of 2.5 mg/m3.
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14. Evaluation of human health risks
14.1. Assessment of health risks
Very little information has been found in the peer-reviewed literature on the toxic
effects of TGIC. Several cases of allergic contact dermatitis have been reported
subsequent to occupational exposure. However, no relevant peer-reviewed
experimental studies that explore the potency of TGIC to induce allergic contact
dermatitis have been found. This renders assessment of the sensitising potential of
TGIC problematic. Two cases of occupational asthma have been described but the
significance of these findings remains to be clarified.
TGIC has been shown to produce mutations in vitro in bacterial test systems
and chromosomal aberrations in CHO and CHL cells. In addition, there are non
peer-reviewed in vivo studies in male mice that demonstrate induction of chromo-
somal aberrations in germ cells. Thus, even though TGIC has not been shown to
be carcinogenic in experimental animals or in humans, genotoxic effects of TGIC
may have relevance for reproductive and developmental toxicity. In line with
these observations is the finding that TGIC causes a dose-dependent reduction in
the number of spermatozoa in rats and reduced male fertility in mice.
The toxic effects of TGIC of concern are its sensitising properties, genotoxicity
and effects on reproduction. In addition TGIC may cause serious eye damage.
14.2. Groups at extra risk
Based on the data evaluated, no identification of groups or individuals at extra
risk in the human population can be made.
14.3. Scientific basis for an occupational exposure limit
TGIC has a genotoxic potential both in vitro and in vivo, it reduces the number of
spermatozoa in rats, reduces male fertility in mice and causes allergic contact
dermatitis. These effects are relevant to reproduction toxicity and development
through a genotoxic mechanism, and sensitisation. At the present state of
knowledge it is not possible to identify a dose or exposure level at which these
adverse effects do not occur.
15. Research needs
In view of the potential hazards of TGIC there is a remarkable lack of peer-
reviewed data with respect to mutagenicity, genotoxicity and carcinogenicity.
Further studies are also needed to clarify the reproductive toxicity of TGIC. Data
on absorption of TGIC following inhalation and dermal exposure would be of
interest. The sensitising potential of TGIC should be experimentally determined
in relevant animal tests and in epidemiological studies in man.
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16. Summary
Lindell B, Montelius J. Triglycidyl isocyanurate. Arbete och Hälsa 2001;18:1-30.
Triglycidyl isocyanurate (TGIC) is a solid, slightly soluble in water. It has a very
low vapour pressure, and will therefore occur as dust at the workplace. TGIC is an
epoxy compound containing three epoxy groups. Technical TGIC is a mixture of
the α- and ß-isomer. TGIC is often used as a hardener. The main use is in the
manufacture of polyester powder coatings for metal finishing. The powder coatings
usually contain between 4 and 10% TGIC. There is little information found with
respect to the toxicokinetics of TGIC. However, some data on α-TGIC indicate that
TGIC is rapidly and extensively metabolised.
TGIC may cause allergic contact dermatitis in humans. Several cases have been
reported subsequent to occupational exposure. However, the contact sensitising
potential of TGIC remains to be established. TGIC has been shown to be
mutagenic/genotoxic in vitro. Furthermore, there are data that demonstrate a
genotoxic potential of TGIC in vivo. A reduction in male fertility and a dose-related
decrease in the number of spermatozoa has also been reported in animals. Experi-
mental animal studies indicate that TGIC instilled into the eyes may cause severe
eye damage.
The major concerns for human health are contact allergy, mutagenicity/geno-
toxicity and reproductive toxicity. At the present state of knowledge it is not
possible to identify a dose or exposure level at which these adverse effects do not
occur.
Keywords: allergic contact dermatitis, eye damage, genotoxicity, occupational
exposure limits, mutagenicity, powder coating, reproductive toxicity, risk
assessment, TGIC, toxicity, triglycidyl isocyanurate.
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17. Summary in Swedish
Lindell B, Montelius J. Triglycidyl isocyanurate. Arbete och Hälsa 2001;18:1-30.
Triglycidylisocyanurat (TGIC) är ett fast ämne, något lösligt i vatten. Det har
mycket lågt ångtryck och förekommer därför som damm i arbetsmiljön. TGIC är
en epoxiförening och innehåller tre epoxigrupper. Tekniskt TGIC är en blandning
av α- och ß-isomeren. TGIC används ofta som härdare, framför allt vid tillverk-
ning av pulverlacker av polyestertyp avsedda för ytbehandling av metall. Pulver-
lackerna innehåller vanligen mellan 4 och 10% TGIC. Informationen om upptag
och omsättning av TGIC är sparsam, men data gällande α-TGIC antyder att
metabolismen av TGIC är snabb och omfattande.
TGIC kan förorsaka allergiskt kontakteksem hos människa. Åtskilliga fall har
rapporterats i samband med yrkesmässig exponering, men ämnets
kontaktsensibiliserande potential återstår att fastställa. TGIC har visats vara
mutagent/genotoxiskt in vitro. Andra data visar att TGIC är genotoxiskt in vivo.
Minskad fertilitet och en dos-relaterad minskning av antalet spermier har också
rapporterats hos handjur. Djurexperimentella studier indikerar att TGIC kan
förorsaka svåra ögonskador vid instillation i ögat.
De toxiska effekter som framför allt inger oro vid yrkesmässig exponering för
TGIC är kontaktallergi, mutagenicitet/genotoxicitet och reproduktionstoxicitet.
Med dagens kunskap är det inte möjligt att identifiera en dos eller
exponeringsnivå vid vilken dessa effekter inte uppträder.
Nyckelord: allergiskt kontakteksem, genotoxicitet, gränsvärden, mutagenicitet,
pulverlacker, reproduktionstoxicitet, riskbedömning, TGIC, toxicitet,
triglycidylisocyanurat, ögonskada.
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19. Data bases used in the search for literature
The following data bases were used in the search for literature:
- Arbline
- Chemical Abstracts
- CISDOC
- HSELINE
- Medline
- MHIDAS
- NIOSHTIC
- RILOSH
- Toxline
Last search was performed 2001-11-22.
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Appendix 1
Occupational exposure limits for triglycidyl isocyanurate in air.
Country mg/m3 Comments Year Ref
Denmark - - 2000 1
Finland - - 1998 2
Germany - 2000 3
Iceland - - 1999 4
Netherlands 0.1 - 2001 5
Norway - - 2001 6
Sweden - - 2000 7
United Kingdom 0.1 - 1998 8
USA (ACGIH) 0.05 - 2001 9
 (NIOSH) - - 2000 10
 (OSHA) - - 2000 10
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